Brain activity and walking problems in cerebral small vessel disease
Studies brain activity linked to walking trouble in older adults with cerebral small vessel disease.
Key facts
- Who runs it
- Ain Shams University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Neural Correlates (EEG and fMRI) of Gait in Small Vessel Disease
- Status
- Not yet recruiting
- People taking part
- 40 people, planned
- Started
- 1 Mar 2026
- Expected to end
- 1 Mar 2027
- Type of study
- Observational, 2 groups
- Treatments tested
- No Intervention: Observational
- Record updated
- 3 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 or older with cerebral small vessel disease and slowly worsening walking problems. Healthy adults of similar age can also join as a comparison group.
- Age
- 50 years or older
- Sex
- All sexes
- Disease stage
- Cerebral small vessel disease confirmed by clinical signs and MRI, with a Fazekas score of 2 or 3. Walking problems must come on slowly (slowness, poor balance, freezing), not from a sudden stroke.
- Biomarker or test result
- MRI findings such as white matter hyperintensities, lacunes or microbleeds; Fazekas score 2 or 3 on MRI.
Main reasons for not taking part
- Other brain-wasting diseases, such as Parkinson's disease or Alzheimer's disease
- Past stroke in a large blood vessel or bleeding inside the brain
- Cannot have an MRI, for example due to a pacemaker, metal implants or severe fear of closed spaces
- Severe memory and thinking problems (MoCA <10)
- Walking problems caused by muscle, bone or joint problems rather than the nervous system
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age 50 years or older
- Clinical and radiological diagnosis of cerebral small vessel disease (SVD), confirmed by MRI findings such as white matter hyperintensities, lacunes, or microbleeds
- Fazekas score 2 or 3 on MRI
- Presence of slowly progressive gait disturbance (e.g., slowness, imbalance, freezing) rather than acute stroke presentation; Ability to give informed consent and cooperate with testing procedures
Who cannot take part
- Contraindications to MRI (e.g., pacemaker, metallic implants, severe claustrophobia)
- Presence of other neurodegenerative disorders (e.g., Parkinson's disease, Alzheimer's disease)
- History of large vessel stroke or intracerebral hemorrhage
- Severe cognitive impairment that prevents participation (MoCA <10)
- Musculoskeletal or orthopedic causes of gait disturbance not related to neurological dysfunction
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
What is the purpose of this study? This observational study is being done to understand how cerebral small vessel disease (SVD) affects walking and balance. SVD is a common brain condition in older adults that damages small blood vessels. It can lead to problems with movement, thinking, and memory. The researchers want to find out how changes in brain activity and connectivity contribute to walking difficulties in people with SVD.
Read full original descriptionShow less
Why is this study important? Walking and balance problems increase the risk of falls and loss of independence. By studying brain activity during walking-related tasks, researchers hope to identify patterns that explain why these problems happen. This knowledge could help develop better rehabilitation methods in the future.
Who can participate? Adults over 50 years old with cerebral small vessel disease and gradual gait problems may be eligible. Healthy adults of similar age without neurological problems may also take part as control participants.
What will happen in this study?
Participants will:
Complete walking, balance, and cognitive tests such as the Timed Up and Go, Berg Balance Scale, and Montreal Cognitive Assessment.
Undergo brain imaging (MRI) to confirm the diagnosis and study brain structure and function.
Have an EEG recording while resting and while watching short videos showing walking and turning movements.
A smaller group will also undergo functional MRI (fMRI) while watching the same videos.
The MRI and EEG results will be analyzed to see how brain networks involved in movement and balance differ between patients and healthy adults.
How long will the study take? The study will take about two years to complete. Each participant's visit will last approximately two to three hours in total.
What are the possible benefits? There may be no direct benefit to participants. However, this study may help researchers understand how small vessel disease affects brain function related to walking, which may improve care for future patients.
The 2 groups in the trial
- Healthy Controls
Age matched adults with no neurological disorders or gait impairments and normal MRI findings. Participants will undergo the same clinical, EEG, and MRI assessments as the patient group.
Treatment: No Intervention: Observational
- SVD Patients
dults aged 50 years or older diagnosed with cerebral small vessel disease (SVD) showing gait disturbance confirmed by MRI (Fazekas score 2-3). Participants will undergo clinical assessment, EEG, and functional MRI.
Treatment: No Intervention: Observational
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Investigating Neural Correlates of Gait Abnormalities in Patients With Cerebral Small Vessel Disease
- Plain-language title
- Brain activity and walking problems in cerebral small vessel diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 3 February 2026